ALLE
44
14
MPC
65
3
IPG
45
-7
LUV
76
-3
UNP
40
-3
IFF
63
3
AA
58
2
SNA
72
19
FLR
68
12
CHD
34
3
MRK
41
-2
ECL
59
2
SO
73
23
HBAN
59
5
MDLZ
59
9
SRE
45
3
PCAR
30
-4
PNC
59
2
LEG
48
2
HRL
30
-2
ALLE
44
14
MPC
65
3
IPG
45
-7
LUV
76
-3
UNP
40
-3
IFF
63
3
AA
58
2
SNA
72
19
FLR
68
12
CHD
34
3
MRK
41
-2
ECL
59
2
SO
73
23
HBAN
59
5
MDLZ
59
9
SRE
45
3
PCAR
30
-4
PNC
59
2
LEG
48
2
HRL
30
-2
Financhill
Back

UroGen Pharma 10K Form

Buy
62

URGN
UroGen Pharma

Last Price:
$15.12
Seasonality Move:
0.45%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2023-11-14 10Q URGN/UroGen Pharma Quarterly
2023-08-10 10Q URGN/UroGen Pharma Quarterly
2023-05-11 10Q URGN/UroGen Pharma Quarterly
2022-11-10 10Q URGN/UroGen Pharma Quarterly
2022-08-11 10Q URGN/UroGen Pharma Quarterly
2022-05-10 10Q URGN/UroGen Pharma Quarterly

Receive URGN News And Ratings

See the #1 stock for the next 7 days that we like better than URGN

URGN Financial Statistics

Sales & Book Value

Annual Sales: $90.4M
Cash Flow: $-42.1M
Price / Cash Flow: 0
Annual Sales: $-1.01
Price / Book: 16.41

Profitability

EPS (TTM): -3.18000
Net Income (TTM): $-138.4M
Gross Margin: $81.5M
Return on Equity: 0%
Return on Assets: -52.53%

UroGen Pharma Earnings Forecast

Key UroGen Pharma Financial Ratios

  • The Gross Profit Margin over the past 10 years for URGN is 90.18%.
  • The Selling, General & Administrative Expenses for URGN have been equal to 134.02% of Gross Profit Margin.
  • The Research & Development expenses have been 63.21% of Revenue.
  • The Net Earning history of URGN is -140.35% of Total Revenues.
  • Per Share Earnings over the last 10 years have been positive in 5 years.

UroGen Pharma Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: URGN
CUSIP: M96088
Website: urogen.com

Debt

Debt-to-Equity Ratio: -2.63
Current Ratio: 5.65
Quick Ratio: 5.13

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

URGN Technical Analysis vs Fundamental Analysis

Buy
62
UroGen Pharma (URGN) is a Buy

Is UroGen Pharma a Buy or a Sell?

  • UroGen Pharma stock is rated a Buy
    The current UroGen Pharma [URGN] share price is $15.41. The Score for URGN is 62, which is 24% above its historic median score of 50, and infers lower risk than normal.